Since the pioneering results of the Framingham study disclosed in 1971, 1) hypercholesterolemia has been recognized as a major risk factor for the development of coronary heart disease (CHD).
Since the pioneering results of the Framingham study disclosed in 1971, 1) hypercholesterolemia has been recognized as a major risk factor for the development of coronary heart disease (CHD). 2, 3) Agents controlling total plasma cholesterol levels are expected to serve as an effective therapeutic method for atherosclerosis, 4) since lowering plasma cholesterol levels has been proven to reduce mortality from myocardial infarction.
5) Acyl-CoA: cholesterol O-acyltransferase (ACAT, EC 2.3.1.26) 6, 7) is an intracellular enzyme responsible for catalyzing the esterification of free cholesterol with fatty acyl-CoA to produce cholesteryl esters. This enzyme plays important roles in the absorption of dietary cholesterol from the small intestine, the secretion of very lowdensity lipoprotein (VLDL) from the liver, and the accumulation of cholesteryl esters in atherosclerotic lesions. Inhibition of ACAT should reduce the absorption of cholesterol, lower plasma cholesterol levels, [8] [9] [10] [11] [12] and should arrest the progression and promote the regression of atherosclerotic plaque. 13, 14) Therefore, ACAT inhibitors are a prime objective in the development of new therapeutic agents for hypercholesterolemia and atherosclerosis. 15) On this basis, metabolites were screened from about three thousand fungi and numerous plant components that produce an ACAT inhibitor. Of these, it was found that 1-(4-hydroxy-3-methoxyphenyl)-7-phenylhept-1-en-3-one (1, Yakuchinone B), which is a component of the seeds of Alpinia oxyphylla MIQUEL (Zingiberaceae), 16) has ACAT inhibitory activity. In order to obtain ACAT inhibitors that exhibit a high level of hypocholesterolemic activity in vivo, the structure-activity relationships of three structural moieties of Yakuchinone B (1) as the lead compound ( Fig. 1) were examined. The compounds prepared were tested for the ability to inhibit the microsomal ACAT from rat liver and to suppress the elevation of plasma cholesterol levels in rats given a high cholesterol diet.
The present paper will describe the structure-activity relationships and biological activities of these novel ACAT inhibitors.
Chemistry Diarylheptanoids (1-7) were synthesized by condensation of 1-phenyl-5-hexanone with corresponding benzaldehydes according to the previously described method. 17) As shown in Chart 1, phenylalkylamides (11, (13) (14) (15) or anilides (12, 17, 18) were prepared by alkylation of 8, followed by amidation with appropriate phenylalkylamine or aniline by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) in CHCl 3 .
Phenylpiperamides (16, can be synthesized from 8 via intermediates 9a, b or 10a, b (Chart 1). In the case of the modification of region C in the molecule (Fig. 1) , phenylpiperamides (16, (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) were prepared by alkylation of 8 with corresponding halide, followed by amidation with appropriate phenylpiperazine. With modification of region A in the molecule (Fig. 1) , phenylpiperamides (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (42) (43) (44) (45) (46) were prepared by amidation of 8 with corresponding phenylpiperazine, followed by alkylation with appropriate halide.
Biology The ability to inhibit hepatic ACAT in vitro was measured by incubating [1- 14 C]oleoyl-CoA with microsome fractions prepared from the liver of Sprague-Dawley rats given a normal diet. ACAT inhibitory activity was expressed by IC 50 .
In vivo hypocholesterolemic activity was assessed in these rats by admixing a test compound into their diet at a concentration of 0.005 or 0.1% for four days. For the next three days the rats were fed a high cholesterol diet containing a test compound at the same concentration (nϭ8). For this investigation the dosages of each compound calculated from the body weight and the food consumption during the study period were about 5 and 70-80 mg/kg/d for each concentration. Cholesterol lowering effect expressed as an inhibitory rate (%) was calculated as follows: cholesterol lowering effect (%)ϭ[(BϪA)/(BϪC)]ϫ100 (A, B, and C represent plasma total cholesterol levels in the drug-treated, control, and normal groups, respectively).
Results and Discussion
To obtain ACAT inhibitors that exhibit a high level of hypocholesterolemic activity in vivo, the structure-activity relationships for three structural regions ( Fig. 1 ) of Yakuchinone B (1) were examined as a lead compound.
The Structure-Activity Relationships for Region A The biological data for Yakuchinone B (1) and its derivatives (2-7), substituted on the A-phenyl ring, has been shown in Table 1 . Compound 1 inhibited rat hepatic ACAT with an IC 50 value of 20.6 mM. When an acetyl residue was introduced at R 2 of 1 (2), ACAT inhibitory activity increased by 2.1 times. Compound 3, which had a benzyl residue at R 2 , showed higher activity than 2. However, compound 4, which had a benzoyl residue at R 2 , exhibited only a weak ACAT inhibitory activity. The ACAT inhibitory activity of 5, which did not have a methoxy residue like that at R 1 of 3, was remarkably lower than that of 3. Compound 6, which had an ethoxy residue instead of a methoxy residue of 3 at R 1 , exhibited almost the same activity as 3. Compound 7, which had another methoxy residue like that at R 3 of 3, provided greater inhibition of ACAT than 3.
These data indicate that compound 7 with methoxy residues at R 1 and R 3 and a benzyl residue at R 2 in the Aphenyl ring exhibited excellent ACAT inhibitory activity. On the other hand, compounds 1-7 were not able to suppress a rise in the plasma total cholesterol levels when the derivative was mixed in the diet at a concentration of 0.1% and administered at a dose of 70-80 mg/kg/d to rats given a high cholesterol diet. The reason for the weak hypocholesterolemic activity in vivo for these compounds is not clear, but may be related to poor efficacy for ACAT inhibition and/or to low bioavailability. Next, we synthesized the derivatives of compound 7 and examined the ACAT inhibitory activity in vitro and hypocholesterolemic activity in vivo.
The Structure-Activity Relationships of Regions B and C The amide compounds CI-976 8, 18, 19) and FR129169 20) ( Fig. 2) are excellent ACAT inhibitors. Therefore, introduction of the amino units into region B of 7 was investigated in order to further increase ACAT inhibitory activity. As shown in Table 2 , introduction of a n-propylamino-linker in region B (11) increased ACAT inhibitory activity by 2 times, as we expected. Additionally, derivative 12 in which an aminolinker or 16 in which a tertiary amine of a piperazino-linker was introduced in region B had higher inhibitory activity of rat hepatic ACAT than 11. ACAT inhibitory activity decreased in the following order: amino (12)Ͼpiperazino (16)Ͼn-propylamino (11)Լn-butylamino (15)Ͼ Ͼethylamino (14)ϭn-butyl (7)Ͼ Ͼmethylamino (13). Further, ACAT inhibitory activity markedly increased with the introduction of methyl residues to the C-phenyl ring of 12 and 16 (17) (18) (19) (20) . In particular, 19, which had a piperazino-linker in region B and methyl residues at positions 2 and 4 in the C-phenyl ring, significantly inhibited the elevation of plasma total cholesterol levels in rats given a high cholesterol diet when administered as a dietary admixture at a concentration of 0.1%. On the other hand, 17, which had methyl residues at positions 2 and 4 in the C-phenyl ring like 19 but which had an amino-linker in region B, did not exhibit hypocholesterolemic activity. Moreover, 20, which was a structural isomer of 19 with a similar ACAT inhibitory pro- file in vitro, did not exhibit hypocholesterolemic activity.
The Structure-Activity Relationships of 19 and Its Derivatives Derivatives of 19 were synthesized with substitution in the A-and C-phenyl rings as their ability to inhibit microsomal ACAT from the liver of rats and hypocholesterolemic activity in vivo was investigated. In addition, the concentration of the derivatives added to the diet was set at 0.005% to select derivatives that were more potent than 19. For this investigation, the dosage of each derivative was about 5 mg/kg/d. Biological data for 19 and its derivatives 21-46 is shown in Table 3 .
Although 19 inhibited the elevation in plasma total cholesterol levels when administered as a dietary admixture at a concentration of 0.1% (Table 2) , it did not exhibit hypocholesterolemic activity when administered at a concentration of 0.005% (Table 3) .
In respect to derivatives of 19 with substitution in the Aphenyl ring, conversion of benzyl residue of 19 into a 3-phenylpropyl (21) or phenoxyethyl (22) residue decreased ACAT inhibitory activities in vitro, and these derivatives did not produce significant hypocholesterolemic activity. Next, benzyl residue of 19 was converted into a geranyl, farnecyl or n-alkyl residue, since it seemed that the ACAT inhibitory activity might increase by the introduction of a long-chain aliphatic moiety with a structure similar to an acyl residue of an acyl-CoA which was one substrate for ACAT.
When benzyl residue of 19 was converted into a geranyl (23) or farnecyl (24) residue, inhibitory activity on hepatic ACAT increased in a striking manner as we expected. However, these compounds did not exhibit hypocholesterolemic activity. Conversion of benzyl residue of 19 into an n-heptyl (26) , n-octyl (27) , n-nonyl (28), or n-decyl (29) residue but not an n-hexyl (25) residue significantly increased ACAT inhibitory activity.
In addition, the hypocholesterolemic activity of n-alkyl derivatives increased according to the length of the alkyl chain, and n-octyl (27) , n-nonyl (28) , and n-decyl (29) derivatives produced significant hypocholesterolemic activity when administered as a dietary admixture at a concentration of 0.005%. Although 23 and 24 inhibited ACAT in a more striking fashion than 29, these derivatives did not exhibit hypocholesterolemic activity. Based on these results, it is assumed that the elevation in this activity with the introduction of a long n-alkyl residue is related not only to an increase in their specific activity with respect to ACAT but also to other factors such as their increased bioavailability.
On the other hand, 30, which had an n-decyl residue in the A-phenyl ring but no residue in the C-phenyl ring, did not lower plasma cholesterol level. This result suggests that appropriate substituents in the C-phenyl ring are needed to exhibit hypocholesterolemic activity.
The structure-activity relationship studies of the derivatives with substituents in the C-phenyl ring, which had an ndecyl residue at R 2 in the A-phenyl ring (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) , indicate the following. Results for monomethyl-substituted compounds (31) (32) (33) demonstrated that a 4-methyl residue was very important in exhibiting a high level of hypocholesterolemic activity in vivo, while a 2-methyl or 3-methyl residue was not.
With respect to a 4-substituent in the C-phenyl ring, methyl (33) , tert-butyl (34), methoxy (35) , and fluorine (36) analogs had a higher level of ACAT inhibitory activity than a nitro analog (37) . Therefore, the electrical nature of the substituents did not clearly correlate with their ACAT inhibitory activity. On the other hand, methyl (33) , tert-butyl (34), or methoxy (35) analogs, which were electron-donating groups, had a higher level of hypocholesterolemic activity in vivo than those with fluorine (36) or nitro (37) , which were electron-withdrawing groups. These results indicated that although the electrical properties of C-phenyl substituents did not affect specific activity with respect to ACAT, the effectiveness of lowering plasma cholesterol level in vivo was largely influenced by the electrical properties of those substituents. The supposition is that the introduction of electrondonating groups in the C-phenyl ring at position 4 influenced their pharmacokinetics, such as absorption, distribution, and clearance, as with the introduction of a long-chain alkyl residue at R 2 in the A-phenyl ring, so in vivo hypocholesterolemic activity increased. Factors determining the potency of ACAT inhibitors of in vivo hypocholesterolemic activity are being analyzed through the comparison of the pharmacokinetics of the ACAT inhibitors that were synthesized. These results will be reported later.
With respect to dimethyl-substituted compounds (29, 38-42), a 3,4-dimethyl-substituted derivative (42) had more of an effect in lowering cholesterol level than a 4-methyl substituted derivative (33) or a 2,4-dimethyl substituted derivative (29) .
With respect to A-phenyl substituted derivatives that had two methyl residues in the C-phenyl ring at positions 3 and 4 (42) (43) (44) (45) (46) , n-heptyl (44) , n-octyl (45) , n-nonyl (46) , and ndecyl (42) derivatives produced significant hypocholesterolemic activity. For these derivatives, unlike those with a 2,4-dimethyl residue in the C-phenyl ring (25) (26) (27) (28) (29) , the drug efficacy did not increase according to the length of the nalkyl chain at R 2 in the A-phenyl ring, and the n-octyl derivative (45) had the highest level of hypocholesterolemic activity.
From the structure-activity relationship studies on three structural regions using Yakuchinone B (1) as a lead compound, 45, N- (3,5- Fig. 2 ) was finally synthesized.
Biological Activities of 45 As shown in Table 4 , 45 more strongly inhibited rat hepatic ACAT than did other ACAT inhibitors (an amide compound CI-976 and a urea compound YM750 21) ) and had a level of hypocholesterolemic activity in vivo that was as high as that with CI-976 and YM750.
A number of potent ACAT inhibitors that exhibit excellent hypocholesterolemic activity in various species have been synthesized for the purpose of pharmaceutical development, [22] [23] [24] and some of these have demonstrated highly satisfactory results in model animals. Clinical development of ACAT inhibitors, however, has not been successful, 25, 26) be- [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Recently, ACAT has been classified into two isozymes, ACAT-1 and ACAT-2, and research suggests that they differ in terms of their distribution in the body. [39] [40] [41] [42] [43] Two reasons are believed to be involved in why the numerous ACAT inhibitors that have been developed thus far have not been clinically successful.
One is the relationship between adrenotoxicity and the inhibition of ACAT-1, which was found ubiquitously throughout the body including macrophages and adrenal glands. Tanaka et al. reported that since a compound with a high level of macrophage ACAT (ACAT-1) inhibitory activity induced adrenal toxicity, there might be a positive correlation between specific activity with respect to ACAT-1 and adrenotoxicity. 37) On the other hand, Dominick et al. 29) and Sliskovic et al. 33) reported that the adrenotoxicity observed with ACAT inhibitors was likely to be independent of ACAT inhibition. Thus, it is still unclear as to whether or not adrenotoxicity is related to specific activity for ACAT-1 inhibition. As shown in Table 4 , 45 strongly inhibited microsomal ACAT from HepG2, in which ACAT-1 was predominantly expressed. 42) On the other hand, in subacute toxicity studies of 45 using rats, which abundantly expressed ACAT-1 in adrenal glands, 43) no adrenotoxicity was observed when it was orally administered via a stomach tube once a day to the animals at a dose of 500 mg/kg/d for four weeks (data not shown). Reindel et al. reported that in 2 weeks of oral toxicity studies on PD 132301-2, an urea compound ACAT inhibitor, principal toxicity occurred in adrenals and that the susceptibility for adrenal toxicity of this compound differed among species: rank order of the toxicity (minimal toxic dose, mg/kg) was dogs (6)Ͼguinea pigs (30)Ͼrabbits (30)Ͼmonkeys (50)Ͼrats (1000)Ͼhamsters (no lesions at 1000 mg/kg). 38) From this report, it suggests that subacute toxicity of compound 45 prefers to assess in other species, such as dogs and guinea pigs, because susceptibility for adrenal toxicity of this compound also seems different between species like that of PD 132301-2.
Another reason why numerous ACAT inhibitors did not provide clinical success seems to relate to the large differences in the distribution of ACAT-1 and ACAT-2 in the liver and intestines with respect to humans and rodents. In the liver and intestines of mice, ACAT-2 is predominantly expressed 41) and produces ACAT activity. Additionally, in the liver of rats, it seems that ACAT-2 is predominantly expressed, whereas the expression of ACAT-1 is detected in the intestines. 43) On the other hand, research has shown that ACAT-1 is predominantly expressed in the human liver and that both ACAT-1 and ACAT-2 play a major role in human intestines. 42) Based on these reports, one can speculate that with selective inhibitors for isozymes, the results in model animals such as mice and rats might be quite different from those of clinical studies in humans. As shown in Table 4 , 45 strongly inhibited microsomal ACAT prepared from HepG2 (human hepatocarcinoma), in which ACAT-1 isozyme is expressed predominantly as in human liver tissue. 42) On the other hand, 45 also strongly inhibited microsomal ACAT prepared from differentiating Caco2 (human colon adenocarcinoma) with properties like intestinal epithelial cells, in which both ACAT-1 and ACAT-2 are expressed to the same extent as in human intestinal tissue. 42) Because the IC 50 values for the inhibition of microsomal ACAT derived from the two cell lines were the same, it is assumed that 45 might have sufficient ability to inhibit ACAT in both the human intestines and liver regardless of the pattern of expression of ACAT isozymes.
Although there remains much to explore through clinical studies of 45 as to whether the inhibition of intestinal ACAT or of hepatic ACAT plays a greater role in the treatment of hypercholesterolemia in humans, the results mentioned suggest that 45 might be an effective therapeutic agent for this condition.
Conclusion
A novel series of amide compounds were synthesized to find a new ACAT inhibitor, which exhibited a high level of hypocholesterolemic activity in vivo, using Yakuchinone B (1) as a starting material. Among the compounds synthesized, N-(3,5-dimethoxy-4-n-octyloxycinnamoyl)-NЈ-(3,4-dimethylphenyl)piperazine (45) strongly inhibited rat hepatic ACAT to a level higher than that with CI-976 and YM750, and it exhibited a high level of in vivo hypocholesterolemic activity equivalent to that of CI-976 and YM750. Moreover, since 45 strongly inhibited the microsomal ACAT prepared from human cell lines (Caco2, HepG2), there is speculation that it might have the ability to inhibit ACAT in both the human intestines and the liver. Thus, 45 has fulfilled expectations for its use as a new therapeutic drug for hypercholesterolemia and atherosclerosis.
Experimental
General Procedures All melting points (mp) were determined on an Ishii micromelting point apparatus. IR spectra were recorded on a Shimadzu IR435 spectrophotometer as KBr disks. 1 H-NMR spectra were measured with a JEOL JNM-A400 (400 MHz) instrument. Chemical shifts were reported in d units from tetramethylsilane as the internal standard. Coupling constants (J) were reported in hertz. Mass spectra were obtained with a Hitachi M-80B mass spectrometer using electron impact (EI) for ionization, and data were exhibited as m/z. Elemental analyses were carried out on a CHN Coder MT-3 (Yanagimoto MFG. Co., Ltd., Kyoto, Japan). The reagents and solvents used were obtained from commercial suppliers without further purification. Column chromatography was performed on silica gel (Merck; particle size 0.063-0.200 mm). Reaction progress was checked by TLC analysis on silica gel coated glass plates (Kieselgel 60 F 254 , thickness of 0.25 mm). Visualization was with UV light (254 nm) or iodine.
Yakuchinone B (1), 17) CI-976 18) and YM750 21) were synthesized according to the previously described method in our laboratories. 4-tert-Butylphenylpiperazine, 2,6-dimethylphenylpiperazine, 3,4-dimethylphenylpiperazine, and 3,5-dimethylphenylpiperazine were prepared from bis(2-chloroethyl)-N-(ethoxycarbonyl)amine and corresponding anilines according to the procedure described by Mishani et al. 44) a) In vitro ACAT inhibition was measured using microsomes isolated from rat livers, HepG2, or Caco2. Each determination was performed in triplicate. b) Hypocholesterolemic activity expressed as an effective dose to reduce plasma total cholesterol levels by 50% of the control value (nϭ8). Acetyloxy-3-methoxyphenyl)-7-phenylhept-1-en-3-one (2 The following compounds 3-7 were prepared in a manner similar to that described for 2 from 1-phenyl-5-hexanone and the appropriate benzaldehyde.
1-(4-
1-(4-Benzyloxy-3-methoxyphenyl)-7-phenylhept-1-en-3-one (3) 4-Benzyloxy-3,5-dimethoxycinnamic Acid (9a) 3,5-Dimethoxy-4-hydroxycinnamic acid 8 (124.8 g, 556.6 mmol) was dissolved in EtOH (1.5 l) and H 2 SO 4 (50 ml) was added dropwise to this mixture under an ice-cold condition and then refluxed at 100°C for 5.5 h. After cooling to room temperature, the reaction mixture was concentrated and poured into water (4.5 l) and the resulting precipitate was collected by filtration and dried in vacuo to give ethyl 3,5-dimethoxy-4-hydroxycinnamate (131.4 g, yield 93.6%). Ethyl 3,5-dimethoxy-4-hydroxycinnamate (30.00 g, 118.9 mmol) was dissolved in N,N-dimethylformamide (DMF) (500 ml) and then sodium hydride (10.88 g of 60% in oil, 272.2 mmol) was added very carefully to this solution. Benzyl chloride (18.05 g, 142.2 mmol) was added to this mixture portionwise and the mixture was stirred at room temperature for 96 h. The reaction mixture was poured into water (2 l) and the resulting precipitate was collected by filtration. The precipitate was purified by silica gel column chromatography (CHCl 3 ) and dried in vacuo to give ethyl 4-benzyloxy-3,5-dimethoxycinnamate as white crystals (40.12 g, yield 99.3%). 1 N aq. NaOH (65 ml, 65 mmol) was added to a solution of ethyl 4-benzyloxy-3,5-dimethoxycinnamate (1.97 g, 5.8 mmol) in ethanol (100 ml). The mixture was stirred for 7 d at room temperature. Then, the reaction mixture was acidified with 1 N aq. HCl and was concentrated. This solution was then poured into water (2 l). The resulting precipitate was collected by filtration, washed with water, and dried to give 9a as white crystals (1.63 g, yield 89.5%). mp 110-112°C. and sodium hydride (1.81 g, 45.2 mmol) was then very carefully added to this solution. 1-Bromodecane (10.00 g, 45.2 mmol) was added to this mixture portionwise and the mixture was stirred at room temperature for 96 h. The reaction mixture was poured into water (5 l) and was adjusted at pH 3 with 1 N aq. HCl. Ethyl 4-n-decyloxy-3,5-dimethoxycinnamate was extracted with CHCl 3 (2 l) and the extracts were dried with sodium sulfate anhydrous. The solvent was removed in vacuo to give ethyl 4-n-decyloxy-3,5-dimethoxycinnamate as a clear oil which was used for the next reaction without purification. To the solution of ethyl 4-n-decyloxy-3,5-dimethoxycinnamate in EtOH (250 ml) was added 1 N aq. NaOH (65 ml, 65 mmol) followed by stirring for 4 d at room temperature. Then, 1 N aq. HCl was added to the reaction mixture and concentrated. This solution was then poured into water (2 l N-(3,5-Dimethoxy-4-hydroxycinnamoyl)-N-(2,4-dimethylphenyl) piperazine (10a) EDC (8.55 g, 44.6 mmol) and 1-(2,4-dimethylphenyl)-piperazine (8.49 g, 44.6 mmol) were added to a solution of 8 (10.00 g, 44.6 mmol) in CHCl 3 (600 ml) and stirred overnight at room temperature. The reaction mixture was directly purified by silica gel column chromatography (CHCl 3 ) and recrystallized from EtOH to give 10a as pale yellow crystals (5.06 g, yield 28.6%). mp 213-215°C. The following compounds 12-15, 17, 18 were prepared in a manner similar to that described for 11 from 9a and the appropriate aniline or phenylalkylamine. (4H, br s), 3.81 (4H, br s), 3.88 (6H, s) 
N-Phenyl-(2E)-3-(4-benzyloxy-3,5-dimethoxyphenyl)-2-propenamide

N-Benzyl-(2E)-3-(4-benzyloxy-3,5-dimethoxyphenyl)-2-propenamide
